NDT editorial

Title: Renal Fanconi syndrome: taking a proximal look at the nephron

Enriko D Klootwijk, Markus Reichold, Robert J Unwin, Robert Kleta, Richard Warth, Detlef Bockenhauer

Correspondence to:

Professor Robert Kleta, MD, PhD, FASN, FACMG
Potter Chair of Nephrology
University College London
Royal Free Hospital / Medical School
Rowland Hill Street, London NW3 2PF, United Kingdom

phone: +44-20-7317 7554
fax: +44-20-7472 6476
email: r.kleta@ucl.ac.uk

1

Summary

Renal Fanconi Syndrome (RFS) refers to the generalised dysfunction of the proximal tubule (PT) [1]. In its isolated form, RFS only affects the PT, but not the other nephron segments. The study of isolated RFS can thus provide specific insights into the function of the PT. In a recent paper, Klootwijk et al., investigated one such form of isolated RFS and revealed the underlying molecular basis [2]. The affected family had been described previously, demonstrating the typical features of RFS, such as low-molecular weight proteinuria, aminoaciduria, glycosuria and phosphaturia with consequent rickets; yet, importantly, patients had no evidence of impaired glomerular filtration [3]. Inheritance was consistent with an autosomal dominant mode. Klootwijk et al. discovered a surprising explanation: a heterozygous missense mutation causing partial mistargeting of the peroxisomal enzyme EHHADH to the mitochondria. Notably, disease causing was not the absence of the enzyme in the peroxisome, but its interference with mitochondrial function. The discovery of this novel disease mechanism not only confirmed the importance of mitochondrial function for PT transport, but also demonstrated the critical dependence of PT on fatty acid metabolism for energy generation.

The review:

Proximal tubule: function and physiology

In an average adult, the kidneys (glomeruli) generate approximately 150 litres of filtrate per day, of which about 99% is reabsorbed by the tubules, yielding a urine volume of 1-2 litres (Figure 1) [4]. The vast majority of the glomerular filtrate is reabsorbed by the PT, the "workhorse" of tubular segments. Insight

into the contributions of the individual nephron segments has been mainly provided by micropuncture experiments, where micropipettes are inserted into different segments of the nephron to measure flow and obtain samples for analysis. This technique has an important limitation, however, in that only those segments that are close to the surface of the kidney are accessible for puncture. Thus, the last accessible site in PT is the end of the proximal convolute and the next accessible site downstream is the beginning of the distal convolute [5]. In between these two sites is the straight descending PT (the pars recta or S3 segment) and the loop of Henle and it is impossible to accurately determine the individual contributions of these segments. Whilst the function of all nephron segments including those not accessible by the micropuncture technique has been studied using the technique of isolated tubule perfusion, quantitative information with respect to relative transport activity in vivo is difficult to extrapolate [6].

In any case, the PT not only reabsorbs the vast majority of filtrate in terms of salt and water, but also is the sole site of reabsorption for many valuable solutes, such as amino- and organic acids, filtered proteins, glucose and phosphate. In quantitative terms, without a functional PT, we would lose approximately 120 litres of water per day, plus solutes, including about 18 mol of sodium (the equivalent of roughly 1 kg of cooking salt) and more than 100 g of sugar. In addition, all the filtered amino acids would be lost, deficiency of which can be associated with specific diseases [7], as well as all filtered phosphate, resulting in hypophosphataemic rickets. In short: the PT is important for our survival! In addition, it becomes evident from those numbers that RFS refers to an impairment of PT function, rather than a complete absence of function.

The enormous reabsorptive capacity is provided by a whole orchestra of specialised apical, basolateral and paracellular permeabilities and driven by the electrochemical gradient generated by the basolateral Na^+-K^+-ATPase (see Figure 2). Not surprisingly, the PT has a high energy demand to keep the transport going, which may explain, why it is also the nephron segment most susceptible to ischaemic damage [8]. Understanding PT function thus will not only elucidate the pathophysiology of the rare RFS, but may also provide insights into the more common problem of acute kidney injury [9].

RFS: the history

Rickets and albuminuria secondary to kidney disease was first described in 1881 but attributed to be a "disorder of adolescence" [10]. It was the Swiss paediatrician Guido Fanconi, who first described the concept that defective renal proximal tubule reabsorption of solutes might contribute to "non-nephrotic glycosuric dwarfing with hypophosphataemic rickets in early childhood" [11]. Fanconi's first case presented at the age of 3 months with rickets and recurrent fevers. She had glycosuria and albuminuria and progressed to terminal renal failure by 5 years of age and subsequently died. At autopsy the renal tubule cells appeared filled with crystals, which were thought to be cystine. In subsequent reports, Debré, de Toni and Fanconi all described series of children with rickets, glycosuria and albuminuria [12-14]. In acknowledgment of this pioneering work, RFS is also referred to as Fanconi-Debré-de Toni syndrome, but in clinical practice most people use the shorter name. The presentation, course and outcome of the children described in these early descriptions varied markedly and this concurs with our clinical experience now. It reflects that RFS is not a

uniform entity, but a diagnosis of proximal tubular dysfunction, which can be due to a variety of different causes. RFS can be isolated, such as in the family investigated by Klootwijk et al., or in the context of multiorgan disorders, such as nephropathic cystinosis or mitochondrial cytopathies; it can be congenital or acquired, transient or permanent, associated with progression to end-stage kidney disease (ESKD) or with stable glomerular filtration [15-17]. Moreover, it can differ in the extent and severity of tubular dysfunction. Severe and generalised PT dysfunction is seen in nephropathic cystinosis, whilst some patients with e.g. Dent disease or Lowe syndrome have wasting of low-molecular weight proteins and calcium, yet without clinically significant disturbance of phosphate and bicarbonate transport [18]. Indeed, there is some debate at what point proximal tubular dysfunction can be called RFS [1]. There seems to be agreement that several individual PT functions have to be compromised and isolated renal tubular aminoacidurias (e.g., cystinuria or Hartnup disorder) would not be labelled as renal Fanconi syndrome. Dissecting the various pathways involved in these individual diseases of course contributes to our understanding of PT function.

RFS: the inheritance

There are several genetic forms of RFS, the majority of which are associated with multisystem disorders (Table 1). In general, the disease mechanism for these disorders can be categorised as either a) accumulation of a toxic metabolite (e.g. cystinosis, tyrosinaemia, galactosaemia, Fanconi-Bickel, congenital fructose intolerance and Wilson's disease), b) disruption of energy provision (e.g.

mitochondrial cytopathies) or c) disruption of endocytosis and intracellular transport (e.g. Lowe syndrome, Dent disease and ARC syndrome).

Recently, RFS was described in some patients with MODY1 ("maturity-onset diabetes of the young" type 1) [19]. Interestingly, this renal phenotype was seen only in patients with a specific heterozygous mutation, R76W in HNF4A, whereas those patients with other mutations in HNF4A suffered from pancreatic beta cell dysfunction only. Since HNF4A is a transcription factor, this finding suggests a specific effect of the R76W mutation on transcription of certain genes in the kidney, but which ones exactly are affected is unknown.

Of special interest are, of course, the forms of isolated RFS, as these may provide the most specific insight into PT function. Three genetic forms have been described (Table 1): Fanconi Renotubular Syndrome (FRTS) types 1-3. The first one was published already in 2001, including linkage to a locus on chromosome 15, yet identification of the underlying gene is yet awaited [20]. Of note, FRTS1 is also associated with progressive chronic kidney disease (CKD). Thus, identification of the underlying problem may also elucidate a mechanism of CKD progression. Other families with a similar phenotype of RFS and progressive CKD inherited in an autosomal dominant fashion had been described previously [21-23], suggesting that this may be a slightly more common form of these otherwise very rare diseases.

FRTS2 has so far been described only in 2 siblings. An initial clinical description was provided in 1988 [24], revealing a phenotype dominated by phosphate wasting and rickets despite elevated levels of 1,25 OH vitamin D with associated disturbances of some, but not all PT transport pathways, as e.g. renal tubular acidosis was not present , raising again the question of what constitutes RFS [1].

In 2010, an underlying mutation was reported in form of a homozygous in-frame 21 bp duplication in *SLC34A1*, encoding the phosphate transporter NaPi-IIa [25]. In vitro studies demonstrated significant loss-of-function of the mutant transporter. The finding of SLC34A1 mutations in RFS has been surprising, given that mutations in *SLC34A3*, encoding another renal phosphate transporter NaPi-IIc, cause hereditary hypophosphataemic rickets with hypercalciuria [26]. No further patients with RFS and recessive mutations in SLC34A1 have so far been reported. The genetic finding, however, is consistent with the clinical observation of phosphate wasting and rickets being the key clinical abnormalities in these two siblings and that the phenotype could be ameliorated by phosphate supplementation. The underlying mechanism may be intracellular phosphate depletion with consequent insufficient ATP generation. Abnormalities in an unrelated proximal transport pathway has been observed in mice with hypophosphataemic rickets [27] and glycosuria is indeed a common observation in patients with hypophosphataemic rickets in our own clinical practice. However, other indicators of PT dysfunction, such as low-molecular weight proteinuria are normal in these patients (unpublished own observations).

FRTS3 is the form of isolated RFS that was investigated by our laboratory and reported by Klootwijk et al. [2]. We studied the five generation family described by Tolaymat et al. [3]. Reassessment of the clinical phenotype confirmed the original observations made by Tolaymat et al.. Moreover, it demonstrated normal age-appropriate GFR in all affected family members, including the by then 74-year old matriarch. This alone provided valuable insights: the life-long loss of water and solutes, including about 1g/d of filtered proteins does not appear to be a critical risk factor for the development of CKD.

With respect to revealing the underlying genetic cause we first performed linkage analysis, which identified a single locus on chromosome 3. Sequencing of all known genes within this locus revealed a heterozygous missense mutation in a gene called *EHHADH* that segregated with the disease. *EHHADH* encodes a bifunctional enzyme involved in peroxisomal fatty acid metabolism (also called L-PBE for L-peroxisomal bifunctional enzyme). The identification of *EHHADH* as the underlying gene was initially surprising: the patients did not have a clinical phenotype consistent with a peroxisomal disorder, which typically comprises severe CNS involvement [28]. Moreover, the function of Ehhadh in mice appears to be at least partially redundant, as knock-out mice do not have an apparent abnormal phenotype, except for some changes in lipid metabolites after fasting [29]. They only develop a relevant clinical phenotype, when the related enzyme D-PBE is also deleted [30, 31]. So how does a heterozygote missense mutation in a gene cause disease, when we know that complete loss-of-function can easily be tolerated (at least in mice)? The solution to this conundrum came closer with the realisation that the identified mutation (c.7G>A, p.E3K) introduced a de novo N-terminal mitochondrial targeting motif and indeed, subsequent cell-biological studies confirmed a mitochondrial localisation of the mutated enzyme. Could the mutant enzyme perhaps impair the function of the erroneously targeted organelle, the mitochondria? To address this question, we performed respirometry in proximal tubular cells expressing either wild type or mutant EHHADH, which indeed demonstrated a significantly decreased capacity for oxidative phosphorylation in the mutant cells compared to wild type, compatible with a defect in ATP production. Thus, we concluded that mistargeting of EHHADH led to a dominant negative effect on mitochondrial function,

presumably by interference with the mitochondrial trifunctional enzyme. This enzyme is a multimeric protein involved in mitochondrial fatty acid oxidation and has a high degree of homology to EHHADH, so that erroneous assembly of mutant mislocalised EHHADH into this enzyme may occur. Subsequent co-immunoprecipitation experiments confirmed an association of mutant but not wild type EHHADH with two subunits of the trifunctional enzyme, HADHA and HADHB.

This dominant negative effect of mistargeting constitutes a previously unrecognised disease mechanism. Mistargeting of a peroxisomal enzyme to mitochondria had been described as a disease mechanism with a specific variant in AGXT, causing primary hyperoxaluria [32]. However, in this recessive disorder, it is the absence of peroxisomal AGXT activity that is disease causing rather than interference with mitochondrial function, as seen in FRTS3.

A key question, however, remained: why did the affected patients develop an isolated renal phenotype, when the enzyme is also expressed in other tissues? Should not a generalised mitochondrial phenotype be present?

Energy politics of the proximal tubule

The explanation for this conundrum may have several components. One relates to the magnitude of the observed impairment in mitochondrial function: the capacity for oxidative phosphorylation was reduced by approximately 25%; while this was significant, it may be disease-causing (i.e. relevant) only in those tissues with a high metabolic demand, such as the PT. Yet a probably much more important component is a unique feature of PT fuel consumption: the PT does not utilise glucose, but is dependent on fatty acid metabolism [33]! This may

reflect an evolutionary development to maximise glucose provision to the brain, in that all filtered glucose is returned into the bloodstream. However, it makes the PT uniquely susceptible to disturbances in fatty acid metabolism, consistent with the phenotype of FRTS3.

Future research questions

The discovery of new disease genes and mechanisms often generate more questions than answers. Whilst the clinical and genetic data are clear, the precise nature of the mechanism requires further investigations:

Is there biochemical evidence for disturbed fatty acid metabolism? Obtaining these data from the patients would likely be difficult, as plasma levels reflect the overall metabolism, rather than the specific metabolites generated in PT. However, the question could be addressed in the cell culture system developed in our lab. Alternatively, cell lines could be established from proximal tubular cells shed in the urine, as described in other disorders [34]. PT cells as model to study these questions need to be differentiated as only then glucose metabolism reflects the situation of the PT in vivo. This is not the case for many PT cell lines, especially not if they are not differentiated on permeable supports.

Given the insight provided by the investigation of FRTS3, a key question is, of course, the nature of the disease mechanism in another form of RFS, FRTS1. What is the underlying gene and how does it cause RFS and CKD?

Last, but not least: what lessons from the study of rare disease can be translated to benefit the treatment of common disease? RFTS3 clearly has highlighted the importance of fatty acid metabolism for PT function. Could this be used therapeutically, e.g. in the prevention or treatment of acute kidney injury (AKI)?

There is some evidence that it might: Increased levels of certain free fatty acids have been associated with increased graft survival in renal transplant patients [35]. The fatty acid binding protein L-FABP, functions of which include the promotion of fatty acid metabolism, has been identified not only as a biomarker, but also as a protective factor in AKI (reviewed in [36]).

Thus, the journey of discovery is ongoing!

Transparency declarations:

None to declare.

References

1. Kleta R. Fanconi or not Fanconi? Lowe syndrome revisited. Clin J Am Soc Nephrol 2008;3(5):1244-1245
2. Klootwijk ED, Reichold M, Helip-Wooley A, *et al.* Mistargeting of peroxisomal EHHADH and inherited renal Fanconi's syndrome. N Engl J Med 2014;370(2):129-138
3. Tolaymat A, Sakarcan A, Neiberger R. Idiopathic Fanconi syndrome in a family. Part I. Clinical aspects. J Am Soc Nephrol 1992;2(8):1310-1317
4. Kleta R, Bockenhauer D. Bartter syndromes and other salt-losing tubulopathies. Nephron. Physiology 2006;104(2):p73-80
5. Bockenhauer D, Cruwys M, Kleta R, *et al.* Antenatal Bartter's syndrome: why is this not a lethal condition? QJM : monthly journal of the Association of Physicians 2008;101(12):927-942
6. Pohl M, Shan Q, Petsch T, *et al.* Short-Term Functional Adaptation of Aquaporin-1 Surface Expression in the Proximal Tubule, a Component of Glomerulotubular Balance. J Am Soc Nephrol 2014, in press
7. Camargo SM, Bockenhauer D, Kleta R. Aminoacidurias: Clinical and molecular aspects. Kidney Int 2008;73(8):918-925
8. Ashworth SL, Molitoris BA. Pathophysiology and functional significance of apical membrane disruption during ischemia. Curr Opin Nephrol Hypertens 1999;8(4):449-458
9. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 2012;380(9843):756-766
10. Lucas RC. On a Form of Late Rickets associated with Albuminuria, Rickets of Adolescence. Lancet 1883:993-994
11. Fanconi G. Die nicht diabetischen Glykosurien und Hyperglykaemien des aelteren Kindes. Jahrbuch fuer Kinderheilkunde 1931;133:257-300
12. de Toni G. Remarks on the Relationship between Renal Rickets (Renal Dwarfism) and Renal Diabetes. Acta Pediatrica 1933;16:479-484
13. Debre R, Marie J, Cleret F, *et al.* Rachitisme tardif coexistant avec une Nephrite chronique et une Glycosurie. Archive de Medicine des Enfants 1934;37:597-606
14. Fanconi G. Der nephrotisch-glykosurische Zwergwuchs mit hypophosphataemischer Rachitis. Deutsche Medizinische Wochenschrift 1936;62:1169-1171
15. Kleta R, Blair SC, Bernardini I, *et al.* Keratopathy of multiple myeloma masquerading as corneal crystals of ocular cystinosis. Mayo Clin Proc 2004;79(3):410-412
16. Magnano L, Fernandez de Larrea C, Cibeira MT, *et al.* Acquired Fanconi syndrome secondary to monoclonal gammopathies: a case series from a single center. Clin Lymphoma Myeloma Leuk 2013;13(5):614-618
17. Sirac C, Bridoux F, Essig M, *et al.* Toward understanding renal Fanconi syndrome: step by step advances through experimental models. Contrib Nephrol 2011;169:247-261
18. Bockenhauer D, Bokenkamp A, van't Hoff W, *et al.* Renal phenotype in Lowe Syndrome: a selective proximal tubular dysfunction. Clinical journal of the American Society of Nephrology : CJASN 2008;3(5):1430-1436

19.   Hamilton AJ, Bingham C, McDonald TJ, *et al.* The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a beta cell phenotype. J Med Genet 2014;51(3):165-169

20.   Lichter-Konecki U, Broman KW, Blau EB, *et al.* Genetic and physical mapping of the locus for autosomal dominant renal Fanconi syndrome, on chromosome 15q15.3. Am J Hum Genet 2001;68(1):264-268

21.   Luder J, Sheldon W. A familial tubular absorption defect of glucose and amino acids. Arch Dis Child 1955;30(150):160-164

22.   Sheldon W, Luder J, Webb B. A Familial Tubular Absorption Defect of Glucose and Amino Acids. Arch Dis Child 1961;36(185):90-95

23.   Wen SF, Friedman AL, Oberley TD. Two case studies from a family with primary Fanconi syndrome. Am J Kidney Dis 1989;13(3):240-246

24.   Tieder M, Arie R, Modai D, *et al.* Elevated serum 1,25-dihydroxyvitamin D concentrations in siblings with primary Fanconi's syndrome. N Engl J Med 1988;319(13):845-849

25.   Magen D, Berger L, Coady MJ, *et al.* A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. N Engl J Med 2010;362(12):1102-1109

26.   Bergwitz C, Roslin NM, Tieder M, *et al.* SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006;78(2):179-192

27.   Muhlbauer RC, Fleisch H. Abnormal renal glucose handling in X-linked hypophosphataemic mice. Clin Sci (Lond) 1991;80(1):71-76

28.   Fujiki Y, Yagita Y, Matsuzaki T. Peroxisome biogenesis disorders: molecular basis for impaired peroxisomal membrane assembly: in metabolic functions and biogenesis of peroxisomes in health and disease. Biochim Biophys Acta 2012;1822(9):1337-1342

29.   Houten SM, Denis S, Argmann CA, *et al.* Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids. J Lipid Res 2012;53(7):1296-1303

30.   Fan CY, Pan J, Usuda N, *et al.* Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 1998;273(25):15639-15645

31.   Jia Y, Qi C, Zhang Z, *et al.* Overexpression of peroxisome proliferator-activated receptor-alpha (PPARalpha)-regulated genes in liver in the absence of peroxisome proliferation in mice deficient in both L- and D-forms of enoyl-CoA hydratase/dehydrogenase enzymes of peroxisomal beta-oxidation system. J Biol Chem 2003;278(47):47232-47239

32.   Danpure CJ. Variable peroxisomal and mitochondrial targeting of alanine: glyoxylate aminotransferase in mammalian evolution and disease. Bioessays 1997;19(4):317-326

33.   Balaban RS, Mandel LJ. Metabolic substrate utilization by rabbit proximal tubule. An NADH fluorescence study. Am J Physiol 1988;254(3 Pt 2):F407-416

34.   Laube GF, Shah V, Stewart VC, *et al.* Glutathione depletion and increased apoptosis rate in human cystinotic proximal tubular cells. Pediatr Nephrol 2006;21(4):503-509

35.   Baker AC, de Mattos A, Watkins S*, et al.* Pretransplant free fatty acids (FFA) and allograft survival in renal transplantation. J Surg Res 2010;164(2):182-187

36.   Alge JL, Arthur JM. Biomarkers of AKI: A Review of Mechanistic Relevance and Potential Therapeutic Implications. Clin J Am Soc Nephrol 2014

Table 1: Genetic forms of RFS

Systemic disorders

Gene	OMIM	Disorder	Associated Features
GALT	230400	Galactosemia	Liver dysfunction, jaundice, encephalopathy, sepsis
Multiple nuclear and mitochondrial DNA variants	multiple	Mitochondrial cytopathies	Usually multisystem dysfunction (brain, muscle, liver, heart)
FAH	276700	Tyrosinemia	Poor growth, hepatic enlargement and dysfunction, liver cancer
ALDOB	229600	Congenital Fructose Intolerance	Rapid onset after fructose ingestion, vomiting, hypoglycemia, hepatomegaly
CTNS	219800	Cystinosis	Poor growth, vomiting, rickets ± corneal cystine crystals, kidney failure
GLUT2	227810	Fanconi Bickel syndrome	Failure to thrive, hepatomegaly, hypoglycemia, rickets
OCRL	309000	Lowe's syndrome	Males (X-linked), cataracts, hypotonia, developmental delay
CLCN5, OCRL	300009, 300555	Dent disease I, II	Males (X-linked), hypercalciuria, nephrocalcinosis
ATP7B	277900	Wilson's disease	Hepatic & neurological disease, Kayser-Fleischer rings
VPS33B, VIPAR	208085, 613404	ARC syndrome	Arthrogryposis, platelet abnormalities, cholestasis
HNF4A	125850	MODY1	neonatal hyperinsulinism, Maturity-onset of diabetes in the young, mutation R76W shows RFS

Isolated RFS

Gene	OMIM	Disorder	Associated Features
?	134600	FRTS1	glomerular kidney failure
SLC34A1	613388	FRTS2	phosphaturia dominating
EHHADH	615605	FRTS3	no kidney failure

Table 2: Key points

- FRTS3 is caused by a mutation in EHHADH

- Discovery of a novel disease mechanism: a dominant negative effect from intracellular mistargeting of the mutated enzyme

- Life long dysfunction of PT including the loss of about 1g/d of filtered proteins alone does not cause chronic kidney disease

- The proximal tubule is dependent on fatty acid metabolism for energy generation

**Figure 1: Genetic renal tubular diseases caused by failure of sodium reabsorption in individual nephron segments**

Fig. 1

Figure 2: Simplified schematic of renal proximal tubular cell with key transepithelial transport systems (note, Cl^- and HCO_3^--transport systems have been omitted).

Fig. 2

lumen   cell   blood